Lexicon Pharmaceuticals (LXRX) Interest & Investment Income (2010 - 2023)
Lexicon Pharmaceuticals (LXRX) posted quarterly Interest & Investment Income of $63000.0 for Q2 2023, up 155.75% year-over-year from $24633.2 in Q2 2022, and down 76.23% quarter-over-quarter from $265000.0 in Q1 2023.
Lexicon Pharmaceuticals (LXRX) Interest & Investment Income (2010 - 2023) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Interest & Investment Income for 14 consecutive years, with $63000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Interest & Investment Income rose 155.75% year-over-year to $63000.0; the TTM figure through Jun 2023 stood at $50000.0 (up 134.25% YoY), while the FY2022 annual figure was -$418000.0, down 10350.0% from the prior year.
- Interest & Investment Income fell to $63000.0 in Q2 2023 per LXRX's latest filing, from $265000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $776000.0 in Q1 2020 and bottomed at -$548000.0 in Q2 2020.
- Historically, Interest & Investment Income has averaged -$4944.4 across 5 years, with a median of -$3000.0 in 2021.
- Annual changes were most pronounced in 2020 — Interest & Investment Income soared 1624.44% — and 2022, when it plunged 34000.0%.
- Lexicon Pharmaceuticals' Interest & Investment Income stood at $48000.0 in 2019, then plunged by 185.42% to -$41000.0 in 2020, then soared by 87.8% to -$5000.0 in 2021, then soared by 1360.0% to $63000.0 in 2022, then changed by 0.0% to $63000.0 in 2023.
- Business Quant data shows LXRX's Interest & Investment Income at $63000.0 in Q2 2023, $265000.0 in Q1 2023, and $63000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 63,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | -341,000.00 |
| Jun 30, 2022 | -113,000.00 |
| Mar 31, 2022 | -27,000.00 |
| Dec 31, 2021 | -5,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | -10,000.00 |
| Mar 31, 2021 | 11,000.00 |
| Dec 31, 2020 | -41,000.00 |
| Sep 30, 2020 | -277,000.00 |
| Jun 30, 2020 | -548,000.00 |
| Mar 31, 2020 | 776,000.00 |
| Dec 31, 2019 | 48,000.00 |
| Sep 30, 2019 | -50,000.00 |
| Jun 30, 2019 | 53,000.00 |
| Mar 31, 2019 | 45,000.00 |
| Dec 31, 2018 | 59,000.00 |
| Sep 30, 2018 | 147,000.00 |